Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on February 10, 2006:
- Previous Holding: 17,739,611 Ordinary Share ADRs
- New Holding: 17,766,181 Ordinary Share ADRs
- Average Price: $51.85
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in these shares as beneficiaries of the discretionary fund, similar to other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the specific transaction described above in accordance with Disclosure Rule 3.1.4R (1) (b).
Investor Verification Points
- Verify the total number of Ordinary Share ADRs held by the US Retirement Savings Plan post-transaction (17,766,181).
- Confirm the average transaction price of $51.85 for the fund movement on February 10, 2006.
- Note the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.